heart palpitations tirzepatide Rate Increase: Evidence and Monitoring Guidance Is Your Heart Racing on

The company announced yesterday that it has officially begun enrolling participants in a Phase 2 trial of pemvidutide, its GLP-1 and glucagon dual receptor agonist, to evaluate the drug in people with Alcohol Use Disorder, or AUD

The startups pipeline includes an injectable GLP-1 receptor agonist in Phase I trials, a dual amylin/calcitonin receptor agonist (DACRA) which is being combined with the GLP-1 agonist, as well as a unimolecular GLP-1/GIP/Glucagon in combination with the DACRA

Josephidou, M., Lynch, A

current clinical evidence shows no mechanism for cardiac atrophy and suggests potential cardiovascular benefits instead

Two reasons why they would do that is theyve either gone off the drug, or their body within six months has adapted to the drug and it overrides what the drug is telling them